These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10327053)

  • 1. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
    Strathdee G; MacKean MJ; Illand M; Brown R
    Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
    Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
    Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
    Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
    Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    Arnold CN; Goel A; Boland CR
    Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
    Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
    Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
    Branch P; Masson M; Aquilina G; Bignami M; Karran P
    Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.
    Deng G; Chen A; Hong J; Chae HS; Kim YS
    Cancer Res; 1999 May; 59(9):2029-33. PubMed ID: 10232580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1.
    Wheeler JM; Beck NE; Kim HC; Tomlinson IP; Mortensen NJ; Bodmer WF
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10296-301. PubMed ID: 10468602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypermethylation of hMLH1 and microsatellite instability in ovarian mucinous tumors].
    Chen HZ; Ye DF; Xie X; Hu M; Lu WG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):457-61. PubMed ID: 12974095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of DNA mismatch repair in acquired resistance to cisplatin.
    Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
    Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of the hMLH1 gene promoter in solitary and multiple gastric cancers with microsatellite instability.
    Sakata K; Tamura G; Endoh Y; Ohmura K; Ogata S; Motoyama T
    Br J Cancer; 2002 Feb; 86(4):564-7. PubMed ID: 11870538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.
    Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M
    Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.
    Deng G; Chen A; Pong E; Kim YS
    Oncogene; 2001 Oct; 20(48):7120-7. PubMed ID: 11704838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia.
    Lenz G; Hutter G; Hiddemann W; Dreyling M
    Ann Hematol; 2004 Oct; 83(10):628-33. PubMed ID: 15309527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite mutations of transforming growth factor-beta receptor type II and caspase-5 occur in human precursor T-cell lymphoblastic lymphomas/leukemias in vivo but are not associated with hMSH2 or hMLH1 promoter methylation.
    Scott S; Kimura T; Ichinohasama R; Bergen S; Magliocco A; Reimer C; Kerviche A; Sheridan D; DeCoteau JF
    Leuk Res; 2003 Jan; 27(1):23-34. PubMed ID: 12479849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients.
    Scartozzi M; De Nictolis M; Galizia E; Carassai P; Bianchi F; Berardi R; Gesuita R; Piga A; Cellerino R; Porfiri E
    Eur J Cancer; 2003 May; 39(8):1144-9. PubMed ID: 12736115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.